**ISPOR 13th Annual European Congress**

6-9 November 2010 • PRAGUE, CZECH REPUBLIC

**CONGRESS AT-A-GLANCE**

### SATURDAY, 6 NOVEMBER

**9:00-18:00** PRE-CONGRESS SHORT COURSES (Short Course registration required)

- **9:00-18:00** All Day Short Courses
  - Introduction to Pharmacoeconomics **Club A (1st)**
  - Discrete Event Simulation for Economic Analysis **Club C (1st)**
- **9:00-13:00** Morning Short Courses
  - Patient Registries **Club H (1st)**
  - Introduction to Patient-Reported Outcomes Assessment: Instrument Development & Evaluation **Club B (1st)**
  - Introduction to Modeling **Meeting Hall IV (2nd)**
  - Bayesian Methods in Economic Evaluations – Intro **Club E (1st)**
- **13:00-14:00** LUNCH (attendees on their own)
- **14:00-18:00** Afternoon Short Courses
  - Meta-Analysis & Systematic Literature Review **Club H (1st)**
  - Retrospective Database Analysis **Meeting Hall V (2nd)**
  - Utility Measurements (Preference-Based Techniques) **Club B (1st)**
  - Pharmacoeconomic Modeling – Applications **Meeting Hall IV (2nd)**
  - Introduction to Health Technology Assessment (HTA) **Club E (1st)**
- **18:15-19:15** EDUCATIONAL SYMPOSIUM
  - Orphan Drugs in Europe: Funding Challenges for Payers & Developers (Sponsored by UBC) **Panorama Hall (1st)**

### SUNDAY, 7 NOVEMBER: MORNING

**8:00-12:00** PRE-CONGRESS SHORT COURSES (Short Course registration required)

- **8:00-12:00** Morning Short Courses
  - Bayesian Methods in Economic Evaluations – Advanced **Club H (1st)**
  - Reimbursement Systems in Europe **Meeting Hall IV (2nd)**
  - Risk-Sharing/Performance-Based Arrangements for Drugs & Other Medical Products **Meeting Hall V (2nd)**
  - Transferability of Cost-Effectiveness Data between Countries **Club B (1st)**
  - Cost-Effectiveness Analysis alongside Clinical Trials **Club E (1st)**
  - Cost Estimation & Assessing Financial (Budget) Impact of New Health Care Technologies **Club A (1st)**
  - Advanced Patient-Reported Outcomes Assessment: Psychometric Methods **Club D (1st)**

### SUNDAY, 7 NOVEMBER: AFTERNOON

**12:00-12:30** EXHIBITS & RESEARCH POSTERS – I **Forum Hall & Congress Hall Foyer (2nd)**

- **12:30-14:15** WELCOME, PRESENTATION OF ISPOR DISTINGUISHED SERVICE AWARDS & 1ST PLENARY SESSION **Congress Hall (2nd)**
  - Improving the Efficiency in Assessment of Health Technology in Europe

- **14:15-14:45** BREAK, EXHIBITS & RESEARCH POSTERS – I **Forum Hall & Congress Hall Foyer (2nd)**

- **14:45-15:45** ISSUE PANELS – I
  - IP1: Are Diagnostics & Personalized Medicine in Flux? Implications of Global Policy Changes for Health Economics & Outcomes Research **Panorama Hall (1st)**
  - IP2: Methods or Pragmatism: Who Should Have the Say in Health Economic Assessment? **Club DE (1st)**
  - IP3: The Value of a QALY: Is There a Single Threshold Value or Does Context Matter? **Club AB (1st)**
  - IP4: Rare (Orphan) Disease: Tension Between Government Support of Developing New Therapies & Reimbursement Processes? Perspectives from EU-5 (Germany, UK, France, Spain & Italy), Central & Eastern Europe, USA & Canada **Club AB (1st)**
  - IP5: Is Any Data Better Than No Data? The Use of Mixed Modalities for PRO Data Collection in Clinical Trials **North Hall (2nd)**

**16:00-17:00** WORKSHOPS – I

- W1: Conducting & Interpreting Indirect Treatment Comparison & Network Meta-Analysis: Learning the Basics **Panorama Hall (1st)**
- W2: The Impact of Disease on Caregivers: A Forgotten Aspect of the NICE Reference Case **Club AB (1st)**
- W3: Methods in Economic Analysis of Patient Support Programs in Aging **Club DE (1st)**
- W4: HTA Influence Mapping: Sourcing the Primary Opinion **North Hall (2nd)**
- W5: How to Address Regional Market Access Hurdles in Decentralised European Countries **Meeting Hall IV (2nd)**
- W7: Health Care Databases for Outcomes Research: Implications of International Variation in Content & Method of Capture **Club H (1st)**

**17:15-18:15** WORKSHOPS – II

- W8: Understanding Mixed Treatment Comparisons (MTCs): What Do the Results Mean & How Should They Be Used? **Meeting Hall IV (2nd)**
- W9: Considering Health as an Investment Rather Than a Cost – Alternative Modelling Approaches to Demonstrate Economic Value **Club AB (1st)**
- W10: Comparing Multiple Strategies in Cost-Effectiveness Analyses **Club DE (1st)**
- W11: Financing Coordinated Care in the European Union **North Hall (2nd)**
- W12: Relative Efficacy: The Possible New Frontier? **Panorama Hall (1st)**
- W13: Modern Methods of Utility Measurement **Meeting Hall V (2nd)**
- W14: Ensuring External Validity in Observational Research **Club H (1st)**

**18:15-19:15** POSTER AUTHOR DISCUSSION HOUR – I **Forum Hall (2nd)**

**18:15-20:00** EXHIBITORS’ OPEN HOUSE RECEPTION **Forum Hall & Congress Hall Foyer (2nd)**

**19:00-20:00** EDUCATIONAL SYMPOSIUM **Congress Hall (2nd)**

- Tools & Methods for Cross-Border Collaboration in HTA (Sponsored by ISPOR & EUnetHTA)

**ISPOR Registration Hours:**

- Saturday, 6 November 8:00-18:00
- Sunday, 7 November 7:00-18:00
- Monday, 8 November 7:00-17:00
- Tuesday, 9 November 7:00-17:00
MONDAY, 8 NOVEMBER

7:00-8:00 EDUCATIONAL SYMPOSIUM
Coping with Chaos: How Can Health Economists Deal with a Multiplicity of Payer Perspectives? (Sponsored by Medaxial) Congress Hall (2nd)

8:00-8:30 EXHIBITS & RESEARCH POSTERS – II
Forum Hall & Congress Hall Foyer (2nd)

8:30-9:45 WELCOME & 2ND PLENARY SESSION Congress Hall (2nd)
Health Technology Assessment (HTA) & Decision-Making in Europe: Balancing Health Care Budgets & Access to Innovation

9:45-10:15 BREAK, EXHIBITS & RESEARCH POSTERS – II
Forum Hall & Congress Hall Foyer (2nd)

10:15-11:15 ISSUE PANELS – II
IP8: Relative Efficacy & Relative Effectiveness: Do Regulatory Agencies & Reimbursement Agencies Have the Same Needs? Panorama Hall (1st)
IP10: How Much Information Do We Need? The Added Value of HRQOL & Genetics Next to Clinical Data in Cancer Management Meeting Hall IV (2nd)

11:30-12:30 RESEARCH PODIUMS – I
Health Care Decision-Maker’s Case Studies Meeting Hall V (2nd)
HTA in Cancer Studies & Methods Panorama Hall (1st)
Developments in Questionnaires EQ-5D & SF-6D Meeting Hall IV (2nd)
Developments in Modeling Methodology Club DE (1st)
Risk Sharing Schemes Club AB (1st)

12:30-14:00 LUNCH, EXHIBITS & RESEARCH POSTERS – II
Forum Hall & Congress Hall Foyer (2nd)

12:45-13:45 EDUCATIONAL SYMPOSIUM Congress Hall (2nd)
Opportunities & Challenges in the Development & Use of Observational Studies for Health Policy Decisions (Sponsored by IMS)

14:00-15:00 ISSUE PANELS – SESSION III
IP12: Reimbursement Issues in Cancer Drugs: Do We Have to Pay for All Cancer Drugs? Congress Hall (2nd)
IP13: EBM, HTA, CER: Clearing the Confusion or Are We Now Confused At a Higher Level? Panorama Hall (1st)
IP14: OALY or the Need for a New Approach? Club DE (1st)

15:00-15:15 BREAK, EXHIBITS & RESEARCH POSTERS – II
Forum Hall & Congress Hall Foyer (2nd)

15:15-16:15 RESEARCH PODIUMS – II
Adherence & Compliance Studies Club AB (1st)
Biologic Agent Studies & Meetings Meeting Hall IV (2nd)
IRI & Rasch Modeling in Quality of Life Measurement Meeting Hall V (2nd)
Mixed Treatment Comparison Methodology & Applications Club DE (1st)
Developments in HTA Agencies Like NICE Panorama Hall (1st)

16:30-17:30 RESEARCH PODIUMS – III
Biases, Methodological Challenges & Solutions Meeting Hall V (2nd)
HTA Policy Approaches Panorama Hall (1st)
Mapping Score from One QoL Measurement into Another Meeting Hall IV (2nd)
Pricing & Market Access Club DE (1st)
HTA in Vaccines & Epidemics Club AB (1st)

17:30-18:30 POSTER AUTHOR DISCUSSION HOUR – II Forum Hall (2nd)

17:30-19:00 EXHIBITORS’ WINE & CHEESE RECEPTION
Forum Hall & Congress Hall Foyer (2nd)

17:30-18:30 ISPOR RUSSIA REGIONAL CHAPTER FORUM
Panorama Hall (1st)

19:30-23:30 ISPOR SOCIAL EVENT: AN EVENING AT ŽOFÍN PALACE
(Separate Registration Required)

TUESDAY, 9 NOVEMBER

7:00-8:00 EDUCATIONAL SYMPOSIUM
A Lack of Local Effectiveness, Cost & Epidemiologic Data: What are the Options for Conducting Pharmaco-economic Studies in Central & Eastern Europe? (Sponsored by Pfizer) Congress Hall (2nd)

8:00-8:30 EXHIBITS & RESEARCH POSTERS – III
Forum Hall & Congress Hall Foyer (2nd)

8:30-9:30 ISPOR FORUMS
ISPOR-SMM: Modeling Good Research Practices Panorama Hall (1st)
ISPOR GRP TF on Prospective Observational Clinical Studies Meeting Hall V (2nd)
Developing Guidelines to Support Quality Improvement of HE Publications Club B (1st)
Comparisons of FDA & EMEA Risk Management Requirements for Recently Approved Products Club A (1st)
HTA: Today’s Decisions, Tomorrow’s Possibilities: Poland, Hungary, Greece & Serbia Club D (1st)
HTA Guidelines in CEE Club E (1st)
Benefits & Barriers of HTA/PE Implementation in the Decision-Making Process Meeting Hall IV (2nd)

9:30-10:00 BREAK, EXHIBITS & RESEARCH POSTERS – III
Forum Hall & Congress Hall Foyer (2nd)

10:00-11:00 ISSUE PANELS – IV
IP16: Can We Use Observational Data to Assess the Cost-Effectiveness of Newly Marketed Drugs? Meeting Hall IV (2nd)
IP17: HTA Level of Influence: To What Extent Do HTAs Influence Market Access Decisions across Geographies? Panorama Hall (1st)
IP18: What Opportunities Are Emerging Today to Harmonise Efforts to Generate Evidence Needed By Regulators, Payers & Drug Developers? Congress Hall (2nd)

11:00-12:00 POSTER AUTHOR DISCUSSION HOUR – III Forum Hall (2nd)

11:30-13:00 LUNCH, EXHIBITS & RESEARCH POSTERS – SESSION III
Forum Hall & Congress Hall Foyer (2nd)

11:45-12:45 EDUCATIONAL SYMPOSIUM Congress Hall (2nd)
Applying HTA across Health Care Systems (Sponsored by EFPIA)

13:00-14:15 WELCOME & 3RD PLENARY SESSION Congress Hall (2nd)
Assessing a Technology with Limited Resources: Building Capacity without Breaking the Bank

14:15-14:30 ISPOR RESEARCH EXCELLENCE AWARD & RESEARCH PRESENTATION AWARDS Congress Hall (2nd)

14:30-14:45 BREAK, EXHIBITS & RESEARCH POSTERS – III Congress Hall (2nd)

14:45-15:45 WORKSHOPS – III
W15: The Use of Large, Simple Trials to Answer CER & Safety Questions Meeting Hall V (2nd)
W16: Model Validation: Buyer Beware Club B (1st)
W17: Challenges & Insights in Establishing & Communicating the Economic Value of Companion Diagnostics Club A (1st)
W18: Time-to-Progression Models: Rapidly Informing Indications in Oncology Club H (1st)
W19: Considerations for Technology Assessments of Diagnostic Products Club E (1st)
W20: Maximum Acceptable Risk: Alternative Measures for Quantifying Patients’ Tolerance for Therapeutic Risks Meeting Hall IV (2nd)

16:00-17:00 WORKSHOPS – IV
W22: Methodological Issues in the Assessment of Comorbidity Influence in Health Outcomes Studies Meeting Hall V (2nd)
W23: Making the Most of Risk-Sharing Schemes: Access Strategies, Risk Analytics & Tactical Sharing Approaches Meeting Hall IV (2nd)
W24: The Netherlands’ First Experiences with Performing Outcomes Research on behalf of Health Care Policymakers: Challenging the Tension between the Optimal & the Feasible Club A (1st)
W25: Brazil as a Case Study of Health Technology Assessment (HTA) on Emerging Markets: How Useful Are Strategies from Developed Countries? Club H (1st)
W27: Development of interim Value Sets for the New 5-Level EQ-5D Descriptive System Club B (1st)
W28: Imputation Techniques to Improve Data Availability from Electronic Medical Records Club D (1st)